07:00 , Jun 23, 2014 |  BC Week In Review  |  Financial News

True North Therapeutics completes venture financing

True North Therapeutics Inc. , South San Francisco, Calif.   Business: Hematology, Renal, Neurology   Date completed: 2014-06-17   Type: Venture financing   Raised: Not disclosed   Investors: Kleiner Perkins Caufield & Byers ; MPM...
00:50 , Jun 18, 2014 |  BC Extra  |  Financial News

True North closes $22 million A round

True North Therapeutics Inc. (South San Francisco, Calif.) raised an undisclosed amount in a tranched $22 million series A round. Kleiner Perkins Caulfield & Byers; MPM Capital; SR One; Biogen Idec New Ventures; and Baxter...
07:00 , Apr 21, 2014 |  BioCentury  |  Emerging Company Profile

True North: Dynamiting complement

True North Therapeutics Inc. 's TNT009 inhibits an upstream target in the classical complement pathway that could lead to greater efficacy and an improved safety profile relative to more advanced complement inhibitors. The single-asset company...
07:00 , Sep 9, 2013 |  BC Week In Review  |  Financial News

True North Therapeutics completes venture financing

True North Therapeutics Inc. , South San Francisco, Calif.   Business: Hematology, Renal, Neurology   Date completed: 9/4/13   Type: Venture financing   Raised: Not disclosed   Investors: SR One; Kleiner Perkins Caufield & Byers;...
07:00 , Sep 9, 2013 |  BC Week In Review  |  Financial News

iPierian completes venture financing

iPierian Inc. , South San Francisco, Calif.   Business: Neurology, Gene/Cell therapy   Date completed: 9/4/13   Type: Venture financing   Raised: Not disclosed   Investors: SR One; Kleiner Perkins Caufield & Byers; MPM Capital;...
00:05 , Sep 5, 2013 |  BC Extra  |  Financial News

iPierian secures $30M, spins out newco for TNT009

iPierian Inc. (South San Francisco, Calif.) secured $30 million in a venture round co-led by existing investors SR One; Kleiner Perkins Caufield & Byers; and MPM Capital. All of iPierian's other existing investors also participated,...
08:00 , Feb 6, 2012 |  BioCentury  |  Finance

Venturing home

While Biogen Idec Inc. (NASDAQ:BIIB) was busy rebooting its R&D last year, the biotech was also quietly shutting down its Biogen Idec New Ventures fund. The decision coincided with the biotech's addition of Douglas Williams...
08:00 , Jan 9, 2012 |  BC Week In Review  |  Financial News

Probiodrug completes venture financing

Probiodrug AG , Halle/Saale, Germany   Business: Neurology, Autoimmune, Inflammation   Date completed: 1/4/12   Type: Venture financing   Raised: €15 million ($19.4 million)   Investors: BB Biotech Ventures; Edmond de Rothschild Investment Partners; LSP-Life...
01:36 , Jan 5, 2012 |  BC Extra  |  Financial News

Probiodrug raises EUR 15 million

Probiodrug AG (Halle/Saale, Germany) raised EUR 15 million ($19.4 million) in a venture round. New investor Wellington Management joined existing investors BB Biotech Ventures; Edmond de Rothschild Investment Partners; LSP-Life Sciences Partners; Biogen Idec New...
07:00 , Sep 13, 2010 |  BC Week In Review  |  Financial News

iPierian financial update

iPierian raised $6 million in a second close of a series B round, bringing the total raised in the round to $28 million. SR One, the venture arm of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.),...